Clinical Policy: Erlotinib (Tarceva)
Reference Number: CP.PHAR74
Effective Date: 09.01.11
Last Review Date: 02.18
Line of Business: Commercial, Health Insurance Marketplace, Medicaid

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
Erlotinib (Tarceva®) is a kinase inhibitor.

FDA Approved Indication(s)
Tarceva is indicated for the treatment of:
• Patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen.
• Patients with locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine as first-line.

Limitation(s) of use:
• Safety and efficacy of Tarceva have not been established in patients with NSCLC whose tumors have other EGFR mutations.
• Tarceva is not recommended for use in combination with platinum based chemotherapy.

Policy/Criteria
Provider must submit documentation (which may include office chart notes and lab results) supporting that member has met all approval criteria

It is the policy of health plans affiliated with Centene Corporation® that Tarceva is medically necessary when the following criteria are met:

I. Initial Approval Criteria
   A. Non-Small Cell Lung Cancer (must meet all):
      1. Diagnosis of NSCLC;
      2. Disease is recurrent or metastatic;
      3. Age ≥ 18 years;
      4. Tumor is positive for an epidermal growth factor receptor (EGFR) exon 19 deletion or EGFR exon 21 (L858R) substitution mutation;
      5. Prescribed by or in consultation with an oncologist;
      6. Request meets one of the following (a or b):
         a. Dose does not exceed 450 mg per day;
         b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).

Approval duration:
B. Pancreatic Cancer (must meet all):
1. Diagnosis of pancreatic cancer;
2. Disease is locally advanced, unresectable, or metastatic;
3. Age ≥ 18 years;
4. Prescribed by or in consultation with an oncologist;
5. Tarceva will be used in combination with gemcitabine;
6. Request meets one of the following (a or b):
   a. Dose does not exceed 450 mg per day;
   b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).

Approval duration:
Medicaid/Health Insurance Marketplace – 6 months
Commercial – Length of Benefit

C. Bone Cancer (off-label) (must meet all):
1. Diagnosis of chordoma;
2. Prescribed by or in consultation with an oncologist
3. Disease is recurrent;
4. Dose is supported by practice guidelines or peer-reviewed literature (prescriber must submit supporting evidence).

Approval duration:
Medicaid/Health Insurance Marketplace – 6 months
Commercial – Length of Benefit

D. Central Nervous System Cancers (off-label) (must meet all):
1. Diagnosis of brain metastases;
2. Disease is recurrent;
3. Prescribed by or in consultation with an oncologist;
4. Tarceva is active against the primary tumor (EGFR sensitizing mutation-positive NSCLC);
5. Dose is supported by practice guidelines or peer-reviewed literature (prescriber must submit supporting evidence).

Approval duration:
Medicaid/Health Insurance Marketplace – 6 months
Commercial – Length of Benefit

E. Kidney Cancer (off-label) (must meet all):
1. Diagnosis of kidney cancer;
2. Disease is relapsed or stage IV with non-clear cell histology;
3. Prescribed by or in consultation with an oncologist;
4. Documentation supports failure of or presence of clinically significant adverse effects or contraindication to at least two FDA approved medications for the relevant diagnosis (e.g., sunitinib, axitinib, bevacizumab, cabozantinib);
5. Dose is supported by practice guidelines or peer-reviewed literature (prescriber must submit supporting evidence).

Approval duration:
Medicaid/Health Insurance Marketplace – 6 months
Commercial – Length of Benefit

F. Other diagnoses/indications
1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid.

II. Continued Therapy
A. All Indications in Section I (must meet all):
1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
2. Prescribed by or in consultation with an oncologist;
3. If request is for a dose increase, request meets one of the following (a or b):
   a. New dose does not exceed 450 mg per day;
   b. New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).

Approval duration:
Medicaid/Health Insurance Marketplace – 12 months
Commercial – Length of Benefit

B. Other diagnoses/indications (must meet 1 or 2):
1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.

   Approval duration: Duration of request or 6 months (whichever is less); or
2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:
A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid or evidence of coverage documents.

IV. Appendices/General Information
Appendix A: Abbreviation/Acronym Key
FDA: Food and Drug Administration
EGFR: epidermal growth factor receptor
NSCLC: non-small cell lung cancer
Appendix B: General Information

- National Comprehensive Cancer Network (NCCN) Practice Guidelines for NSCLC recommend platinum-based chemotherapy regimens for first-line therapy for advanced NSCLC.
- Per NCCN guidelines (category 2A), Tarceva is recommended as first line therapy in patients with advanced, recurrent, or metastatic nonsquamous NSCLC who have known active EGFR mutation or gene amplification regardless of their performance status. This recommendation is based on the results of a phase III trial in which patients with EGFR mutations who received gefitinib had increased progression free survival (25% vs. 7%), response rate (71%) and quality of life and fewer side effects when compared to those receiving chemotherapy (carboplatin/paclitaxel).
- Results from 2 placebo-controlled, randomized, phase III trials showed no clinical benefit with concurrent administration of Tarceva with platinum-based chemotherapy.
- Contraindications to platinum-based chemotherapy regimens may include pre-existing neuropathy, and other complicating comorbidities (e.g. transplant patients; patients with chronic renal insufficiency).
- NCCN Practice Guidelines do not recommend systemic, cytotoxic chemotherapy for patients of any age with a Performance Status (PS) score of 3-4 for NSCLC except Tarceva for EGFR mutation positive patients.
- Tarceva monotherapy for pancreatic cancer has not been studied.
- NCCN recommends Tarceva (2A) as single agent therapy for recurrent chordoma and for relapsed or surgically unresectable stage IV kidney cancer with non-clear cell histology.
- In the IUNO trial examining the use of Tarceva as maintenance therapy in patients with NSCLC without exon 19 deletions or exon 21 (L858R) substitution mutations and without disease progression after four cycles of chemotherapy, Tarceva did not differentiate from placebo on median overall survival or median progression-free survival rates.

Appendix C: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

N/A

V. Dosage and Administration

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>NSCLC</td>
<td>150 mg orally, on an empty stomach, once daily</td>
<td>150 mg per day; 300 mg per day with concurrent tobacco smoking; 450 mg per day if taken with a CYP3A4 inducer</td>
</tr>
<tr>
<td>Pancreatic cancer</td>
<td>100 mg orally, on an empty stomach, once daily</td>
<td>100 mg per day; 300 mg per day with concurrent tobacco smoking; 450 mg per day if taken with a CYP3A4 inducer</td>
</tr>
</tbody>
</table>

VI. Product Availability
Tablets: 25 mg, 100 mg, and 150 mg

VII. References

<table>
<thead>
<tr>
<th>Reviews, Revisions, and Approvals</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Standardized language on continuing therapy with a oncology medication First-line treatment of metastatic NSCLC with EGFR mutations was added Updated the clinical background information</td>
<td>08.13</td>
<td>08.13</td>
</tr>
<tr>
<td>Updated background information to include current 2014 epidemiology Added efficacy data and updated safety information Added ECOG performance status to algorithm Added appendices A – E</td>
<td>07.14</td>
<td>08.14</td>
</tr>
<tr>
<td>Added Tarceva mechanism of action and bioavailability to background. Edited Appendix B: Dosing Combined Appendix E with D Added age limitation to adults per package insert. Added reference to Appendix C wherever asks about toxicity. Replaced monotherapy restriction in the NSCLC questions with the more specific platinum-based therapy restriction per the PI limitations of use section – reflected this edit in the policy’s indications section as well. Supplemented question about performance status (PS) for pancreatic cancer with NCCN guideline language in Appendix D. Supplemented question about PS for NSCLC with NCCN guideline language in Appendix D</td>
<td>6.15</td>
<td>08.15</td>
</tr>
<tr>
<td>Reviews, Revisions, and Approvals</td>
<td>Date</td>
<td>P&amp;T Approval Date</td>
</tr>
<tr>
<td>----------------------------------</td>
<td>------</td>
<td>-------------------</td>
</tr>
<tr>
<td>and added a question under PS 3-4 in the algorithm about EGFR sensitive mutations per NCCN guidelines.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Policy converted to new template. NSCLC: FDA approved use criteria is made slightly less specific to incorporate NCCN compendial uses that are similar but less restrictive. Added one additional “off-label” NSCLC use under Section I.A.2.b. “NCCN recommended use”. Pancreatic cancer: FDA and NCCN indications presented as one criteria set. Additional NCCN uses: all additional NCCN recommended uses are listed under Section C – “other diagnoses/indications”.</td>
<td>06.16</td>
<td>08.16</td>
</tr>
<tr>
<td>Language for NSCLC maintenance therapy changed to “maintenance therapy for metastatic disease after prior chemotherapy”. Maintenance therapy is deleted from the NSCLC NCCN recommended use. Vulvar cancer is added as an additional recommended use. Under section II. Continued Approval, the following edits are made to reasons to discontinue: 1) Added “If pre-existing hepatic impairment or biliary obstruction, a doubling of bilirubin or tripling of transaminase (ALT/AST) values over baseline that does not improve significantly or resolve within 3 weeks”; 2) removed “no disease progression or unacceptable toxicities.”</td>
<td>11.16</td>
<td>12.16</td>
</tr>
<tr>
<td>Updated approval duration to 6 and 12 months; Added NCCN compendium use for pancreatic cancer; Added max dose; Added criteria for off-label uses of Bone cancer – chordoma; Central nervous system cancers-Brain Metastases; and Kidney cancer per NCCN guidelines and compendium. Removed criteria for vulvar cancer since it is a 2b category and only 1 and 2b categories are addressed in the policy. Removed reasons to discontinue per new safety strategy.</td>
<td>08.22.17</td>
<td>11.17</td>
</tr>
<tr>
<td>1Q18 annual review: - Policies combined for Centene Medicaid, Marketplace and Commercial lines of business - Added age to FDA approved indications - For Medicaid NSCLC/ Pancreatic Cancer: replaces specific disease conditions with general language to ensure coverage of both NCCN recommended uses and FDA approved uses - References reviewed and updated</td>
<td>11.14.17</td>
<td>02.18</td>
</tr>
</tbody>
</table>

**Important Reminder**
This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.
Note:
For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

For Health Insurance Marketplace members, when applicable, this policy applies only when the prescribed agent is on your health plan approved formulary. Request for non-formulary drugs must be reviewed using the formulary exception policy.

©2011 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.